14-May-2025 3:05 PM CST - Business Wire Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 3rd Annual H.C. Wainwright BioConnect Investor Conference on Tuesday, May 20th 2025 RBC Capital Markets Global Healthcare Conference Company presentation Wednes
26-Feb-2025 3:01 PM CST - Business Wire Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. 2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue, said Chris Peetz, chief executive officer of Mirum. We continue to expand the reach of our three commercial medicines within our patient communities and look forward to another year of s
14-May-2025 3:05 PM CST - Business Wire Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 3rd Annual H.C. Wainwright BioConnect Investor Conference on Tuesday, May 20th 2025 RBC Capital Markets Global Healthcare Conference Company presentation Wednes
26-Feb-2025 3:01 PM CST - Business Wire Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. 2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue, said Chris Peetz, chief executive officer of Mirum. We continue to expand the reach of our three commercial medicines within our patient communities and look forward to another year of s
